GlassScriptPhysician profile
Carl Snyderman
NPI 1104891258
$6,130.59
in general payments reported to CMS, 2019-2025
6 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $470 · 2022: $46.61 · 2023: $1,670 · 2024: $2,997 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,794 · Travel and Lodging: $1,227 · Food and Beverage: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,794.00 |
| Travel and Lodging | $1,226.70 |
| Food and Beverage | $895.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spiway, LLC | $2,794.00 | 2024 | Spiway |
| Stryker Corporation | $1,918.62 | 2019-2024 | Scopis Ent, Core, Xpress Ent Dilation System |
| Karl Storz Endoscopy-America | $1,011.79 | 2019-2020 | |
| Integra Lifesciences Corporation | $239.38 | 2024-2025 | Acclarent Aera, Trudi Probe, Relieva Spinplus Nav |
| Medtronic, INC. | $166.80 | 2025 | Propel |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$15,582.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Snyderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.